Vergleich

DJ-1 (PARK7, Parkinson Disease (Autosomal Recessive, Early Onset) 7, FLJ27376, Oncogene DJ1)

ArtNr USB-D3790-01D
Hersteller United States Biological
Menge 40 ug
Kategorie
Typ Antibody Polyclonal
Format Lyophilized
Applikationen WB, IHC, ELISA
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus)
Host Rabbit
Isotype IgG
Purity Purified by Immunoaffinity chromatography.
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Versandbedingung Gekühlt
Lieferbar
Manufacturer - Type
Pab
Manufacturer - Category
Antibodies / Antibodies-Oncoproteins
Shipping Temperature
Blue Ice
Storage Conditions
-20°C
Grade
Affinity Purified
Form
Supplied as a lyophilized powder in PBS, pH 7.4, 0.02% sodium azide.
EU Commodity Code
30021010
Immunogen
Synthetic peptide within residues 50-100 of human DJ-1 protein.
Specificity
Recognizes endogenous levels of human DJ-1 protein. Species sequence homology: mouse.
Description
DJ-1 belongs to the C56 peptidase family. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone and a sensor for oxidative stress. It apparently protects neurons against oxidative stress and cell death. Defects in PARK7 gene cause autosomal recessive early-onset Parkinson disease 7. Specifically, defects in PARK7 are characterized by PD onset before the age of 40, slow progression of the condition, and initial good response to levodopa. Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. However, cases of early-onset PD are sometimes found. PD generally arises as a sporadic condition but can be inherited as a simple Mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at an earlier age and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremors, muscular rigidity, and postural instability as well as by a significant clinical response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of protein aggregates) in surviving neurons at various areas of the brain.

Applications:
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 0.05-0.2ug/ml
Western Blot: 0.5-1ug/ml
Immunohistochemistry: 5-10ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Reconstitute with sterile 40-50% glycerol, aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 40 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen